Literature DB >> 4053264

Regional targeting of bisantrene by directed intravascular precipitation.

J S Kovach, M Buck, T Tsukamoto, A Odegaard, M M Lieber.   

Abstract

Targeting of anticancer drugs to specific organs by directed intravascular precipitation was studied in calves using 9-10 anthracenedicarboxyaldehyde bis [(4,5-dihydro-lH-imidazol-2-yl) hydrazone] dihydrochloride (Bisantrene), a clinically active anticancer drug with limited solubility at physiological pH. Rapid injection of Bisantrene in solution at pH 4.5 into the internal iliac artery resulted in concentrations of drug in the urinary bladder wall supplied by the artery that were more than 1000 times those in the same tissue following injection of the same dose of drug IV, the route of administration used clinically. Localization of the orange fluorescent drug to the ipsilateral bladder wall was easily seen. Fluorescence microscopy revealed deposits of drug along the walls of the arteriolar and capillary bed supplied by the artery into which it had been injected. Concentrations of drug in the systemic circulation and in tissues not supplied by the internal iliac artery used for drug injection were lower after intraarterial (IA) drug administration than after IV administration. Pathological studies of the tissues of calves sacrificed at intervals up to four weeks following rapid injection into the internal iliac artery of the same doses of Bisantrene used IV in cancer patients did not reveal evidence of extensive cytotoxicity to the infused organs.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053264     DOI: 10.1007/BF00263884

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04

2.  Pharmacologic rationale for regional drug delivery.

Authors:  J M Collins
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

3.  Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.

Authors:  W H Wu; G Nicolau
Journal:  Cancer Treat Rep       Date:  1982-05

4.  Reversed-phase high-performance liquid chromatographic assay for the antineoplastic agent 9,10-anthracenedicarboxaldehyde bis(4,5-dihydro-1H-imidazol-2-yl hydrazone) dihydrochloride.

Authors:  G Powis
Journal:  J Chromatogr       Date:  1981-12-11

5.  Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).

Authors:  B S Yap; H Y Yap; G R Blumenschein; A Y Bedikian; R Pocelinko; G P Bodey
Journal:  Cancer Treat Rep       Date:  1982-07

6.  Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.

Authors:  G Powis; J S Kovach
Journal:  Cancer Res       Date:  1983-02       Impact factor: 12.701

7.  Phase I clinical trial of 9,10-anthracene dicarboxaldehyde (Bisantrene) administered in a five-day schedule.

Authors:  R J Spiegel; R H Blum; M Levin; C A Pinto; J C Wernz; J L Speyer; K S Hoffman; F M Muggia
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

8.  Parenteral formulation of hexamethylmelamine potentially suitable for use in man.

Authors:  M M Ames; J S Kovach
Journal:  Cancer Treat Rep       Date:  1982-07

9.  Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.

Authors:  D S Alberts; C Mackel; R Pocelinko; S E Salmon
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

10.  Totally implanted drug delivery system for hepatic arterial chemotherapy.

Authors:  W Ensminger; J Niederhuber; S Dakhil; J Thrall; R Wheeler
Journal:  Cancer Treat Rep       Date:  1981 May-Jun
View more
  1 in total

1.  A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer.

Authors:  F A Holmes; L Esparza; H Y Yap; A U Buzdar; G R Blumenschein; G N Hortobagyi
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.